Catherine Pearce - 11 Jan 2023 Form 4 Insider Report for CinCor Pharma, Inc.

Role: Chief Operating Officer
Signature: /s/ Cathy Rude, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 11 Jan 2023
Net transactions value: -$114,914
Form type: 4
Filing time: 19 Jan 2023, 15:34:21 UTC
Previous filing: 13 Jan 2022
Next filing: 30 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CINC	Common Stock	Options Exercise		+13,235	+10%		144,146	11 Jan 2023	Direct	F1
transaction	CINC	Common Stock	Tax liability	$114,914	-3,997	-2.8%	$28.75	140,149	11 Jan 2023	Direct
holding	CINC	Common Stock						1,500	11 Jan 2023	By spouse	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CINC	Restricted Stock Units	Options Exercise	$0	-13,235	-50%	$0.000000	13,236	11 Jan 2023	Common Stock	13,235		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F2	The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein.
F3	The RSUs vest in two equal annual installments beginning January 11, 2023, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.